𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma

✍ Scribed by Jorge E. Romaguera; Luis E. Fayad; Peter McLaughlin; Barbara Pro; Alma Rodriguez; Michael Wang; Pamela Weaver; Kimberly Hartig; Larry W. Kwak; Tatyana Feldman; Judy Smith; Peggy Ford; Stuart Goldberg; Andrew Pecora; Andre Goy

Book ID
108676904
Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
87 KB
Volume
151
Category
Article
ISSN
0007-1048

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase 2 trial of rituximab plus hyper-CV
Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma
✍ Michael Wang; Luis Fayad; Fernando Cabanillas; Fredrick Hagemeister; Peter McLau πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 119 KB

## Abstract ## BACKGROUND. Relapsed or refractory mantle cell lymphoma has a very poor prognosis. The authors evaluated the response rates and survival times of patients treated with an intense regimen known to be effective against untreated aggressive mantle cell lymphoma: rituximab plus hyper‐CV